Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sibeprenlimab for Sjögren’s disease
2024-516295-14-00Phase 2Authorised
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in Sjögren's syndrome comparing Sibeprenlimab with Placebo (2 arms). Primary endpoint: Change from baseline in ESSDAI score. Planned start Sep 2025; status: authorised.
02
Drugs
sibeprenlimab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2024-516295-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516295-14-00.